Key terms
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NBIX news
Today
8:16am ET
Buy Rating on Neurocrine: Strong Foundations and Promising Pipeline
Today
8:08am ET
Oppenheimer Sticks to Its Buy Rating for Neurocrine (NBIX)
Today
7:36am ET
Neurocrine Biosciences: A Balanced Hold Rating Amidst Revenue Growth and Rising Expenses
Today
6:32am ET
Neurocrine’s Innovative Schizophrenia Treatment and Strong Market Strategy Merit a Buy Rating
Today
5:21am ET
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Moderna (MRNA) and Neurocrine (NBIX)
Today
3:50am ET
Neurocrine (NBIX) Receives a Buy from Barclays
Yesterday
11:55pm ET
Buy Rating Affirmed for Neurocrine Biosciences on Strong Performance and Promising Pipeline
Yesterday
8:19am ET
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), Charles River Labs (CRL) and Neurocrine (NBIX)
Yesterday
8:18am ET
Neurocrine’s Hold Rating Affirmed Amid Earnings Shortfall and Steady Sales Outlook
Yesterday
7:16am ET
Neurocrine backs FY24 INGREZZA net product sales view $2.1B-$2.2B
Yesterday
7:15am ET
Neurocrine reports Q1 adjusted EPS $1.20, consensus $1.01
Apr 30
5:15pm ET
Neurocrine announces FDA approval of INGREZZA SPRINKLE capsules
Apr 30
4:12pm ET
Neurocrine management to meet with Oppenheimer
Apr 26
3:15am ET
Promising Outlook for Neurocrine’s NBI-‘845 in MDD Market Based on Strong Phase 2 Results and Competitive Positioning
Apr 26
2:17am ET
Buy Rating Affirmed for Neurocrine on Promising Phase 2 SAVITRI Study Results
Apr 26
2:12am ET
Maintaining Hold on Neurocrine Amid Promising Yet Uncertain Clinical Developments
Apr 24
9:36am ET
Tesla, Airbnb upgraded: Wall Street’s top analyst calls
Apr 24
7:56am ET
Jefferies Sticks to Its Buy Rating for Neurocrine (NBIX)
Apr 24
7:50am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF)
Apr 24
7:30am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX)
Apr 24
6:40am ET
Wall Street Analysts Are Neutral on Top Healthcare Picks
Apr 24
6:21am ET
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)
Apr 24
5:42am ET
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Biogen (BIIB) and Neurocrine (NBIX)
Apr 23
4:41pm ET
Wells Fargo upgrades Neurocrine with pipeline ‘turning a corner’
Apr 23
4:09pm ET
Neurocrine upgraded to Overweight from Equal Weight at Wells Fargo
Apr 23
2:20pm ET
Analysts Are Bullish on These Healthcare Stocks: Neurocrine (NBIX), Carisma Therapeutics (CARM)
Apr 23
10:29am ET
Neurocrine NBI-1065845 results ‘look potentially promising,’ says RBC Capital
Apr 23
9:41am ET
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Neurocrine (NBIX) and Medtronic (MDT)
Apr 23
8:40am ET
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)
Apr 23
7:08am ET
Neurocrine’s NBI-1065845 shows efficacy in major depressive disorder
Apr 16
4:11pm ET
Neurocrine, Sentia Medical Sciences extend CRF research collaboration
No recent press releases are available for NBIX
NBIX Financials
Key terms
Ad Feedback
NBIX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NBIX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
